DivestmentJul 1, 2026, 04:22 PM
Cumberland Completes $100M Asset Sale to Apotex
AI Summary
Cumberland Pharmaceuticals completed the sale of its branded pharmaceutical assets to Apotex for $100 million in cash, following shareholder approval. This strategic divestment strengthens Cumberland's financial position, enabling it to repay a $5.3 million loan and focus resources on its rare disease pipeline, including ifetroban clinical programs. The transaction also involves the transfer of certain personnel to Apotex.
Key Highlights
- Completed sale of branded pharmaceutical assets to Apotex for $100 million cash.
- Shareholders approved the transaction with over 99% of votes cast in favor.
- Terminated and repaid $5.3 million outstanding obligations under a revolving credit loan.
- Company will now focus on developing its ifetroban product candidates for rare diseases.
- Two Vice Presidents will resign from Cumberland and join an Apotex affiliate.
- Unaudited pro forma financial information shows estimated gain on sale of $63.03 million.
- Pro forma cash and cash equivalents increased by $99.24 million.
Price Impact
More from CPIX